Neuronal plasticity and neurotrophic factors in drug responses

Molecular Psychiatry

Volumn 22, Issue 8, 2017, Pages 1085-1095

  Castren E ^a   Antila, H ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; FINGOLIMOD; KETAMINE; NEUROTROPHIC FACTOR; NEUROTROPHIN; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; NERVE GROWTH FACTOR;

ANTIDEPRESSANT ACTIVITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TRANSACTIVATION; ANIMAL; BRAIN CORTEX; DEPRESSION; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBRAL CORTEX; DEPRESSIVE DISORDER; HUMANS; NERVE GROWTH FACTORS; NEURONAL PLASTICITY; RECEPTOR, TRKB; SIGNAL TRANSDUCTION;

EID: 85017506590     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2017.61     Document Type: Review

References (212)

1. Katz LC, Shatz CJ. Synaptic activity and the construction of cortical circuits. Science 1996; 274: 1133–1138.
2. Holtmaat A, Caroni P. Functional and structural underpinnings of neuronal assembly formation in learning. Nat Neurosci 2016; 19: 1553–1562.
3. Castrén E, Hen R. Neuronal plasticity and antidepressant actions. Trends Neurosci 2013; 36: 259–267.
4. Hensch TK. Critical period plasticity in local cortical circuits. Nat Rev Neurosci 2005; 6: 877–888.
5. Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O’leary OF et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008; 320: 385–388.
6. Kobayashi K, Ikeda Y, Sakai A, Yamasaki N, Haneda E, Miyakawa T et al. Reversal of hippocampal neuronal maturation by serotonergic antidepressants. Proc Natl Acad Sci USA 2010; 107: 8434–8439.
7. Sale A, Berardi N, Maffei L. Environment and brain plasticity: towards an endogenous pharmacotherapy. Physiol Rev 2014; 94: 189–234.
8. Morishita H, Hensch TK. Critical period revisited: impact on vision. Curr Opin Neurobiol 2008; 18: 101–107.
9. Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001; 2: 24–32.
10. Thoenen H. Neurotrophins and neuronal plasticity. Science 1995; 270: 593–598.
11. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001; 24: 677–736.
12. Ibanez CF, Andressoo JO. Biology of GDNF and its receptors-relevance for disorders of the central nervous system. Neurobiol Dis 2017; 97: 80–89.
13. Turner CA, Eren-Kocak E, Inui EG, Watson SJ, Akil H. Dysregulated fibroblast growth factor (fgf) signaling in neurological and psychiatric disorders. Semin Cell Dev Biol 2016; 53: 136–143.
14. Rauskolb S, Dombert B, Sendtner M. Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis. Neurobiol Dis 2016; 97: 103–113.
15. Levi-Montalcini R, Cohen S. In vitro and in vivo effects of a nerve growth-stimulating agent isolated from snake venom. Proc Natl Acad Sci USA 1956; 42: 695–699.
16. Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J 1982; 1: 549–553.
17. Barde YA. Trophic factors and neuronal survival. Neuron 1989; 2: 1525–1534.
18. Hohn A, Leibrock J, Bailey K, Barde YA. Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family. Nature 1990; 344: 339–341.
19. Ernfors P, Ibanez CF, Ebendal T, Olson L, Persson H. Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographical expression in the brain. Proc Natl Acad Sci USA 1990; 87: 5454–5458.
20. Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM et al. Neurotrophin-3: a neurotrophic factor related to ngf and bdnf. Science 1990; 247: 1446–1451.
21. Hallböök F, Ibanez CF, Persson H. Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in xenopus ovary. Neuron 1991; 6: 845–858.
22. Berkemeier LR, Winslow JW, Kaplan DR, Nikolics K, Goeddel DV, Rosenthal A. Neurotrophin-5: a novel neurotrophic factor that activates trk and trkb. Neuron 1991; 7: 857–866.
23. Ip NY, Ibanez CF, Nye SH, Mcclain J, Jones PF, Gies DR et al. Mammalian neurotrophin-4: structure, chromosomal localization, tissue distribution, and receptor specificity. Proc Natl Acad Sci USA 1992; 89: 3060–3064.
24. Kaplan DR, Hempstead BL, Martin-Zanca D, Chao MV, Parada LF. The trk proto-oncogene product: a signal transducting receptor for nerve growth factor. Science 1991; 252: 554–558.
25. Klein R, Nanduri V, Jing S, Lamballe F, Tapely P, Bryant S et al. The trk b tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 1991; 66: 395–403.
26. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003; 72: 609–642.
27. Deinhardt K, Chao MV. Trk receptors. Handb Exp Pharmacol 2014; 220: 103–119.
28. Chao MV, Bothwell MA, Ross AH, Koprowski H, Lanahan AA, Buck CR et al. Gene transfer and molecular cloning of the human NGF receptor. Science 1986; 232: 518–521.
29. Radeke MJ, Misko TP, Hsu C, Herzenberg LA, Shooter EM. Gene transfer and molecular cloning of the rat nerve growth factor receptor. Nature 1987; 325: 593–597.
30. Ibanez CF, Simi A. P75 neurotrophin receptor signaling in nervous system injury and degeneration: paradox and opportunity. Trends Neurosci 2012; 35: 431–440.
31. Kraemer BR, Yoon SO, Carter BD. The biological functions and signaling mechanisms of the p75 neurotrophin receptor. Handb Exp Pharmacol 2014; 220: 121–164.
32. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat.Rev.Neurosci 2003; 4: 299–309.
33. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science 2001; 294: 1945–1948.
34. Hempstead BL. Deciphering proneurotrophin actions. Handb Exp Pharmacol 2014; 220: 17–32.
35. Thoenen H. The changing scene of neurotrophic factors. Trends Neurosci 1991; 14: 165–170.
36. Mcallister AK, Katz LC, Lo DC. Neurotrophins and synaptic plasticity. Annu Rev Neurosci 1999; 22: 295–318.
37. Spillantini MG, Aloe L, Alleva E, Desimone R, Goedert M, Levi-Montalcini R. Nerve growth factor mrna and protein increase in hypothalamus in a mouse model of aggression. Proc Natl Acad Sci USA 1989; 86: 8555–8559.
38. Gall CM, Isackson PJ. Limbic seizures increase neuronal production of messenger RNA for nerve growth factor. Science 1989; 245: 758–761.
39. Zafra F, Hengerer B, Leibrock J, Thoenen H, Lindholm D. Activity dependent regulation of bdnf and ngf mrnas in the rat hippocampus is mediated by non-nmda glutamate receptors. EMBO J 1990; 9: 3545–3550.
40. Lu B, Yokoyama M, Dreyfus CF, Black IB. Depolarizing stimuli regulate nerve growth factor gene expression in cultured hippocampal neurons. Proc Natl Acad Sci USA 1991; 88: 6289–6292.
41. Isackson PJ, Huntsman MM, Murray KD, Gall CM. Bdnf mrna expression is increased in adult rat forebrain after limbic seizures: temporal pattern of induction distinct from NGF. Neuron 1991; 6: 937–948.
42. Meyer-Franke A, Wilkinson GA, Kruttgen A, Hu M, Munro E, Hanson MG Jr et al. Depolarization and camp elevation rapidly recruit trkb to the plasma membrane of CNS neurons. Neuron 1998; 21: 681–693.
43. Du J, Feng L, Yang F, Lu B. Activity-and ca(2+)-dependent modulation of surface expression of brain-derived neurotrophic factor receptors in hippocampal neurons. J Cell Biol 2000; 150: 1423–1434.
44. Domenici L, Berardi N, Carmignoto G, Vantini G, Maffei L. Nerve growth factor prevents the amblyopic effects of monocular deprivation. Proc Natl Acad Sci USA 1991; 88: 8811–8815.
45. Maffei L, Berardi N, Domenici L, Parisi V, Pizzorusso T. Nerve growth factor (NGF) prevents the shift in ocular dominance distribution of visual cortical neurons in monocularly deprived rats. J Neurosci 1992; 12: 4651–4662.
46. Berardi N, Maffei L. From visual experience to visual function: roles of neurotrophins. J Neurobiol 1999; 41: 119–126.
47. Castrén E, Maya-Vetencourt JF. Neurotrophins as regulators of visual cortcal plasticity. In: Chalupa LM, Berardi N, M C, Galli-Resta L, Pizzorusso T (eds). Cerebral Plasticity. MIT Press: Cambridge, MA, USA, 2011, pp 343–354.
48. Castrén E, Zafra F, Thoenen H, Lindholm D. Light regulates expression of brain-derived neurotrophic factor mrna in rat visual cortex. Proc Natl Acad Sci USA 1992; 89: 9444–9448.
49. Cabelli RJ, Hohn A, Shatz CJ. Inhibition of ocular dominance column formation by infusion of nt-4/5 or bdnf. Science 1995; 267: 1662–1666.
50. Galuske RA, Kim DS, Castrén E, Thoenen H, Singer W. Brain-derived neurotrophic factor reversed experience-dependent synaptic modifications in kitten visual cortex. Eur J Neurosci 1996; 8: 1554–1559.
51. Cabelli RJ, Shelton DL, Segal RA, Shatz CJ. Blockade of endogenous ligands of trkb inhibits formation of ocular dominance columns. Neuron 1997; 19: 63–76.
52. Galuske RA, Kim DS, Castrén E, Singer W. Differential effects of neurotrophins on ocular dominance plasticity in developing and adult cat visual cortex. Eur J Neurosci 2000; 12: 3315–3330.
53. Lodovichi C, Berardi N, Pizzorusso T, Maffei L. Effects of neurotrophins on cortical plasticity: same or different? J Neurosci 2000; 20: 2155–2165.
54. Cohen-Cory S, Fraser SE. Effects of brain-derived neurotrophic factor on optic axon branching and remodelling in vivo. Nature 1995; 378: 192–196.
55. Mcallister AK, Lo DC, Katz LC. Neurotrophins regulate dendritic growth in developing visual cortex. Neuron 1995; 15: 791–803.
56. Mcallister AK, Katz LC, Lo DC. Neurotrophin regulation of cortical dendritic growth requires activity. Neuron 1996; 17: 1057–1064.
57. Zagrebelsky M, Korte M. Form follows function: Bdnf and its involvement in sculpting the function and structure of synapses. Neuropharmacology 2014; 76: 628–638.
58. Minichiello L. Trkb signalling pathways in ltp and learning. Nat Rev Neurosci 2009; 10: 850–860.
59. Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 2013; 14: 7–23.
60. Castrén E, Pitkänen M, Sirviö J, Parsadanian A, Lindholm D, Thoenen H et al. The induction of LTP increases BDNF and NGF mrna but decreases nt-3 mrna in the dentate gyrus. NeuroReport 1993; 4: 895–898.
61. Patterson SL, Grover LM, Schwartzkroin PA, Bothwell M. Neurotrophin expression in rat hippocampal slices: A stimulus paradigm inducing LTP in ca1 evokes increases in BDNF and nt-3 mrnas. Neuron 1992; 9: 1081–1088.
62. Lohof AM, Ip NY, Poo MM. Potentiation of developing neuromuscular synapses by the neurotrophins nt-3 and bdnf. Nature 1993; 363: 350–353.
63. Kang H, Schuman EM. Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science 1995; 267: 1658–1662.
64. Figurov A, Pozzo-Miller LD, Olafsson P, Wang T, Lu B. Regulation of synaptic responses to high-frequency stimulation and ltp by neurotrophins in the hippocampus. Nature 1996; 381: 706–709.
65. Lessmann V, Gottmann K, Heumann R. Bdnf and nt-4/5 enhance glutamatergic synaptic transmission in cultured hippocampal neurones. NeuroReport 1994; 6: 21–25.
66. Messaoudi E, Bardsen K, Srebro B, Bramham CR. Acute intrahippocampal infusion of bdnf induces lasting potentiation of synaptic transmission in the rat dentate gyrus. J Neurophysiol 1998; 79: 496–499.
67. Panja D, Kenney JW, D’andrea L, Zalfa F, Vedeler A, Wibrand K et al. Two-stage translational control of dentate gyrus LTP consolidation is mediated by sustained BDNF-TrkB signaling to mnk. Cell Rep 2014; 9: 1430–1445.
68. Panja D, Bramham CR. Bdnf mechanisms in late ltp formation: a synthesis and breakdown. Neuropharmacology 2014; 76: 664–676.
69. Kuipers SD, Trentani A, Tiron A, Mao X, Kuhl D, Bramham CR. Bdnf-induced ltp is associated with rapid arc/arg3.1-dependent enhancement in adult hippocampal neurogenesis. Sci Rep 2016; 6: 21222.
70. Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci USA 1995; 92: 8856–8860.
71. Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S et al. Cleavage of probdnf by tpa/plasmin is essential for long-term hippocampal plasticity. Science 2004; 306: 487–491.
72. Korte M, Griesbeck O, Gravel C, Carroll P, Staiger V, Thoenen H et al. Virus-mediated gene transfer into hippocampal ca1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice. Proc Natl Acad Sci USA 1996; 93: 12547–12552.
73. Patterson SL, Abel T, Deuel TA, Martin KC, Rose JC, Kandel ER. Recombinant bdnf rescues deficits in basal synaptic transmission and hippocampal ltp in bdnf knockout mice. Neuron 1996; 16: 1137–1145.
74. Ninan I, Bath KG, Dagar K, Perez-Castro R, Plummer MR, Lee FS et al. The bdnf val66met polymorphism impairs nmda receptor-dependent synaptic plasticity in the hippocampus. J Neurosci 2010; 30: 8866–8870.
75. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al. The BDNF val66met polymorphism affects activity-dependent secretion of bdnf and human memory and hippocampal function. Cell 2003; 112: 257–269.
76. Fritsch B, Reis J, Martinowich K, Schambra HM, Ji Y, Cohen LG et al. Direct current stimulation promotes bdnf-dependent synaptic plasticity: potential implications for motor learning. Neuron 2010; 66: 198–204.
77. Bramham CR, Messaoudi E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 2005; 76: 99–125.
78. Minichiello L, Korte M, Wolfer D, Kuhn R, Unsicker K, Cestari V et al. Essential role for trkb receptors in hippocampus-mediated learning. Neuron 1999; 24: 401–414.
79. Minichiello L, Calella AM, Medina DL, Bonhoeffer T, Klein R, Korte M. Mechanism of trkb-mediated hippocampal long-term potentiation. Neuron 2002; 36: 121–137.
80. Koponen E, Voikar V, Riekki R, Saarelainen T, Rauramaa T, Rauvala H et al. Transgenic mice overexpressing the full-length neurotrophin receptor trkb exhibit increased activation of the trkb-plcgamma pathway, reduced anxiety, and facilitated learning. Mol Cell Neurosci 2004; 26: 166–181.
81. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci 2005; 6: 603–614.
82. Harrington AW, Leiner B, Blechschmitt C, Arevalo JC, Lee R, Morl K et al. Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc Natl Acad Sci USA 2004; 101: 6226–6230.
83. Shulga A, Thomas-Crusells J, Sigl T, Blaesse A, Mestres P, Meyer M et al. Post-traumatic gaba(a)-mediated [ca2+]I increase is essential for the induction of brain-derived neurotrophic factor-dependent survival of mature central neurons. J Neurosci 2008; 28: 6996–7005.
84. Mizui T, Ishikawa Y, Kumanogoh H, Lume M, Matsumoto T, Hara T et al. BDNF pro-peptide actions facilitate hippocampal LTD and are altered by the common BDNF polymorphism Val66Met. Proc Natl Acad Sci USA 2015; 112: E3067–E3074.
85. Guo J, Ji Y, Ding Y, Jiang W, Sun Y, Lu B et al. BDNF pro-peptide regulates dendritic spines via caspase-3. Cell Death Dis 2016; 7: e2264.
86. Volosin M, Trotter C, Cragnolini A, Kenchappa RS, Light M, Hempstead BL et al. Induction of proneurotrophins and activation of p75ntr-mediated apoptosis via neurotrophin receptor-interacting factor in hippocampal neurons after seizures. J Neurosci 2008; 28: 9870–9879.
87. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS et al. Sortilin is essential for prongf-induced neuronal cell death. Nature 2004; 427: 843–848.
88. Zagrebelsky M, Holz A, Dechant G, Barde YA, Bonhoeffer T, Korte M. The p75 neurotrophin receptor negatively modulates dendrite complexity and spine density in hippocampal neurons. J Neurosci 2005; 25: 9989–9999.
89. Koshimizu H, Kiyosue K, Hara T, Hazama S, Suzuki S, Uegaki K et al. Multiple functions of precursor bdnf to cns neurons: negative regulation of neurite growth, spine formation and cell survival. Mol Brain 2009; 2: 27.
90. Deinhardt K, Kim T, Spellman DS, Mains RE, Eipper BA, Neubert TA et al. Neuronal growth cone retraction relies on proneurotrophin receptor signaling through rac. Sci Signal 2011; 4: ra82.
91. Yang F, Je HS, Ji Y, Nagappan G, Hempstead B, Lu B. Pro-bdnf-induced synaptic depression and retraction at developing neuromuscular synapses. J Cell Biol 2009; 185: 727–741.
92. Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA et al. Activation of p75ntr by probdnf facilitates hippocampal long-term depression. Nat Neurosci 2005; 8: 1069–1077.
93. Martinowich K, Schloesser RJ, Lu Y, Jimenez DV, Paredes D, Greene JS et al. Roles of p75(ntr), long-term depression, and cholinergic transmission in anxiety and acute stress coping. Biol Psychiatry 2012; 71: 75–83.
94. Winnubst J, Cheyne JE, Niculescu D, Lohmann C. Spontaneous activity drives local synaptic plasticity in vivo. Neuron 2015; 87: 399–410.
95. Deppmann CD, Mihalas S, Sharma N, Lonze BE, Niebur E, Ginty DD. A model for neuronal competition during development. Science 2008; 320: 369–373.
96. Singh KK, Park KJ, Hong EJ, Kramer BM, Greenberg ME, Kaplan DR et al. Developmental axon pruning mediated by bdnf-p75ntr-dependent axon degeneration. Nat Neurosci 2008; 11: 649–658.
97. Je HS, Yang F, Ji Y, Nagappan G, Hempstead BL, Lu B. Role of pro-brain-derived neurotrophic factor (probdnf) to mature bdnf conversion in activity-dependent competition at developing neuromuscular synapses. Proc Natl Acad Sci USA 2012; 109: 15924–15929.
98. Je HS, Yang F, Ji Y, Potluri S, Fu XQ, Luo ZG et al. Probdnf and mature bdnf as punishment and reward signals for synapse elimination at mouse neuromuscular junctions. J Neurosci 2013; 33: 9957–9962.
99. Thoenen H, Sendtner M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci 2002; 5(suppl): 1046–1050.
100. Bartus RT, Johnson EMJ. Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: where have we been and what have we learned. Neurobiol Dis 2016; 97: 156–168.
101. Josephy-Hernandez S, Jmaeff S, Pirvulescu I, Aboulkassim T, Saragovi HU. Neurotrophin receptor agonists and antagonists as therapeutic agents: an evolving paradigm. Neurobiol Dis 2016; 97: 139–155.
102. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597–606.
103. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012; 64: 238–258.
104. Castrén E. Neuronal network plasticity and recovery from depression. JAMA Psychiatry 2013; 70: 983–989.
105. Lindholm JS, Castrén E. Mice with altered bdnf signaling as models for mood disorders and antidepressant effects. Front Behav Neurosci 2014; 8: 143.
106. Nibuya M, Morinobu S, Duman RS. Regulation of bdnf and trkb mrna in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J.Neurosci 1995; 15: 7539–7547.
107. Dias BG, Banerjee SB, Duman RS, Vaidya VA. Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 2003; 45: 553–563.
108. Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 1999; 21: 679–682.
109. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006; 9: 519–525.
110. Sairanen M, O’leary OF, Knuuttila JE, Castrén E. Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat. Neuroscience 2007; 144: 368–374.
111. Wibrand K, Messaoudi E, Havik B, Steenslid V, Lovlie R, Steen VM et al. Identification of genes co-upregulated with arc during bdnf-induced long-term potentiation in adult rat dentate gyrus in vivo. Eur J Neurosci 2006; 23: 1501–1511.
112. Alme MN, Wibrand K, Dagestad G, Bramham CR. Chronic fluoxetine treatment induces brain region-specific upregulation of genes associated with bdnf-induced long-term potentiation. Neural Plast 2007; 2007: 26496.
113. Russo-Neustadt A, Ha T, Ramirez R, Kesslak JP. Physical activity-antidepressant treatment combination: impact on brain-derived neurotrophic factor and behavior in an animal model. Behav Brain Res 2001; 120: 87–95.
114. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003; 54: 703–709.
115. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, Macdonald E et al. Activation of the trkb neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003; 23: 349–357.
116. Rantamäki T, Hendolin P, Kankaanpaa A, Mijatovic J, Piepponen P, Domenici E et al. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor trkb and induce phospholipase-cgamma signaling pathways in mouse brain. Neuropsychopharmacology 2007; 32: 2152–2162.
117. Rantamäki T, Vesa L, Antila H, Di Lieto A, Tammela P, Schmitt A et al. Antidepressant drugs transactivate trkb neurotrophin receptors in the adult rodent brain independently of bdnf and monoamine transporter blockade. PLoS One 2011; 6: e20567.
118. Chen B, Dowlatshahi D, Macqueen GM, Wang JF, Young LT. Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260–265.
119. Rocha RB, Dondossola ER, Grande AJ, Colonetti T, Ceretta LB, Passos IC et al. Increased bdnf levels after electroconvulsive therapy in patients with major depressive disorder: a meta-analysis study. J Psychiatr Res 2016; 83: 47–53.
120. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase b in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60: 804–815.
121. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004; 101: 10827–10832.
122. Ibarguen-Vargas Y, Surget A, Vourc’h P, Leman S, Andres CR, Gardier AM et al. Deficit in bdnf does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav Brain Res 2009; 202: 245–251.
123. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (bdnf). Pharmacol Biochem Behav 1997; 56: 131–137.
124. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251–3261.
125. Saarelainen T, Vaittinen S, Castrén E. Trkb-receptor activation contributes to the kainate-induced increase in bdnf mrna synthesis. Cell Mol Neurobiol 2001; 21: 429–435.
126. Tuvikene J, Pruunsild P, Orav E, Esvald EE, Timmusk T. Ap-1 transcription factors mediate bdnf-positive feedback loop in cortical neurons. J Neurosci 2016; 36: 1290–1305.
127. Koponen E, Rantamäki T, Voikar V, Saarelainen T, Macdonald E, Castrén E. Enhanced bdnf signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines. Cell Mol Neurobiol 2005; 25: 973–980.
128. Li Y, Luikart BW, Birnbaum S, Chen J, Kwon CH, Kernie SG et al. Trkb regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 2008; 59: 399–412.
129. Arango-Lievano M, Lambert WM, Bath KG, Garabedian MJ, Chao MV, Jeanneteau F. Neurotrophic-priming of glucocorticoid receptor signaling is essential for neuronal plasticity to stress and antidepressant treatment. Proc Natl Acad Sci USA 2015; 112: 15737–15742.
130. Lambert WM, Xu CF, Neubert TA, Chao MV, Garabedian MJ, Jeanneteau FD. Brain-derived neurotrophic factor signaling rewrites the glucocorticoid transcriptome via glucocorticoid receptor phosphorylation. Mol Cell Biol 2013; 33: 3700–3714.
131. Ming GL, Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 2011; 70: 687–702.
132. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104–9110.
133. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805–809.
134. Sahay A, Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci 2007; 10: 1110–1115.
135. Wu X, Castrén E. Co-treatment with diazepam prevents the effects of fluoxetine on the proliferation and survival of hippocampal dentate granule cells. Biol Psychiatry 2009; 66: 5–8.
136. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I et al. Neurogenesis-dependent and-independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009; 62: 479–493.
137. Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA et al. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 2009; 14: 764–773, 739.
138. Sairanen M, Lucas G, Ernfors P, Castrén M, Castrén E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci 2005; 25: 1089–1094.
139. Wang JW, David DJ, Monckton JE, Battaglia F, Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci 2008; 28: 1374–1384.
140. Hajszan T, Dow A, Warner-Schmidt JL, Szigeti-Buck K, Sallam NL, Parducz A et al. Remodeling of hippocampal spine synapses in the rat learned helplessness model of depression. Biol Psychiatry 2009; 65: 392–400.
141. Chen JL, Lin WC, Cha JW, So PT, Kubota Y, Nedivi E. Structural basis for the role of inhibition in facilitating adult brain plasticity. Nat Neurosci 2011; 14: 587–594.
142. Stewart CA, Reid IC. Repeated ecs and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity. Psychopharmacology (Berl) 2000; 148: 217–223.
143. Karpova NN, Pickenhagen A, Lindholm J, Tiraboschi E, Kulesskaya N, Agustsdottir A et al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 2011; 334: 1731–1734.
144. Airan RD, Meltzer LA, Roy M, Gong Y, Chen H, Deisseroth K. High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science 2007; 317: 819–823.
145. Stepan J, Hladky F, Uribe A, Holsboer F, Schmidt MV, Eder M. High-speed imaging reveals opposing effects of chronic stress and antidepressants on neuronal activity propagation through the hippocampal trisynaptic circuit. Front Neural Circuits 2015; 9: 70.
146. Zarate CAJ, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al. A randomized trial of an n-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856–864.
147. Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med 2015; 66: 509–523.
148. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 2016; 22: 238–249.
149. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al. Mtor-dependent synapse formation underlies the rapid antidepressant effects of nmda antagonists. Science 2010; 329: 959–964.
150. Keilhoff G, Bernstein HG, Becker A, Grecksch G, Wolf G. Increased neurogenesis in a rat ketamine model of schizophrenia. Biol Psychiatry 2004; 56: 317–322.
151. Soumier A, Carter RM, Schoenfeld TJ, Cameron HA. New hippocampal neurons mature rapidly in response to ketamine but are not required for its acute antidepressant effects on neophagia in rats. eNeuro 2016; 3: e0116-15.2016.
152. Liu RJ, Lee FS, Li XY, Bambico F, Duman RS, Aghajanian GK. Brain-derived neurotrophic factor val66met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 2012; 71: 996–1005.
153. Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N et al. Brain-derived neurotrophic factor val66met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry 2012; 72: e27–e28.
154. Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS. Bdnf release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol 2014; 18; doi: 10.1093/ijnp/pyu033.
155. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI et al. Nmdar inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016; 533: 481–486.
156. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF et al. Nmda receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91–95.
157. Dagestad G, Kuipers SD, Messaoudi E, Bramham CR. Chronic fluoxetine induces region-specific changes in translation factor eif4e and eef2 activity in the rat brain. Eur J Neurosci 2006; 23: 2814–2818.
158. Lindholm JS, Autio H, Vesa L, Antila H, Lindemann L, Hoener MC et al. The antidepressant-like effects of glutamatergic drugs ketamine and ampa receptor potentiator ly 451646 are preserved in bdnf(+)/(-) heterozygous null mice. Neuropharmacology 2012; 62: 391–397.
159. Brunkhorst R, Vutukuri R, Pfeilschifter W. Fingolimod for the treatment of neurological diseases-state of play and future perspectives. Front Cell Neurosci 2014; 8: 283.
160. Deogracias R, Yazdani M, Dekkers MP, Guy J, Ionescu MC, Vogt KE et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases bdnf levels and improves symptoms of a mouse model of rett syndrome. Proc Natl Acad Sci USA 2012; 109: 14230–14235.
161. Miguez A, Garcia-Diaz Barriga G, Brito V, Straccia M, Giralt A, Gines S et al. Fingolimod (fty720) enhances hippocampal synaptic plasticity and memory in huntington’s disease by preventing p75ntr up-regulation and astrocyte-mediated inflammation. Hum Mol Genet 2015; 24: 4958–4970.
162. Di Nuzzo L, Orlando R, Tognoli C, Di Pietro P, Bertini G, Miele J et al. Antidepressant activity of fingolimod in mice. Pharmacol Res Perspect 2015; 3: e00135.
163. Lee FS, Rajagopal R, Chao MV. Distinctive features of trk neurotrophin receptor transactivation by g protein-coupled receptors. Cytokine Growth Factor Rev 2002; 13: 11–17.
164. Lee FS, Chao MV. Activation of trk neurotrophin receptors in the absence of neurotrophins. Proc Natl Acad Sci USA 2001; 98: 3555–3560.
165. Lee FS, Rajagopal R, Kim AH, Chang PC, Chao MV. Activation of trk neurotrophin receptor signaling by pituitary adenylate cyclase-activating polypeptides. J Biol Chem 2002; 277: 9096–9102.
166. Wiese S, Jablonka S, Holtmann B, Orel N, Rajagopal R, Chao MV et al. Adenosine receptor a2a-r contributes to motoneuron survival by transactivating the tyrosine kinase receptor trkb. Proc Natl Acad Sci USA 2007; 104: 17210–17215.
167. Jeanneteau F, Garabedian MJ, Chao MV. Activation of trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. Proc Natl Acad Sci USA 2008; 105: 4862–4867.
168. Korpi ER, Den Hollander B, Farooq U, Vashchinkina E, Rajkumar R, Nutt DJ et al. Mechanisms of action and persistent neuroplasticity by drugs of abuse. Pharmacol Rev 2015; 67: 872–1004.
169. Lüscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 2011; 69: 650–663.
170. Dong Y, Nestler EJ. The neural rejuvenation hypothesis of cocaine addiction. Trends Pharmacol Sci 2014; 35: 374–383.
171. Ungless MA, Whistler JL, Malenka RC, Bonci A. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 2001; 411: 583–587.
172. Huang YH, Lin Y, Mu P, Lee BR, Brown TE, Wayman G et al. In vivo cocaine experience generates silent synapses. Neuron 2009; 63: 40–47.
173. Lee BR, Ma YY, Huang YH, Wang X, Otaka M, Ishikawa M et al. Maturation of silent synapses in amygdala-accumbens projection contributes to incubation of cocaine craving. Nat Neurosci 2013; 16: 1644–1651.
174. Russo SJ, Mazei-Robison MS, Ables JL, Nestler EJ. Neurotrophic factors and structural plasticity in addiction. Neuropharmacology 2009; 56: 73–82.
175. Lobo MK, Covington HE, Chaudhury D, Friedman AK, Sun H, Damez-Werno D et al. Cell type-specific loss of bdnf signaling mimics optogenetic control of cocaine reward. Science 2010; 330: 385–390.
176. Graham DL, Edwards S, Bachtell RK, Dileone RJ, Rios M, Self DW. Dynamic bdnf activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neurosci 2007; 10: 1029–1037.
177. Graham DL, Krishnan V, Larson EB, Graham A, Edwards S, Bachtell RK et al. Tropomyosin-related kinase b in the mesolimbic dopamine system: region-specific effects on cocaine reward. Biol Psychiatry 2009; 65: 696–701.
178. Koo JW, Mazei-Robison MS, Chaudhury D, Juarez B, Laplant Q, Ferguson D et al. Bdnf is a negative modulator of morphine action. Science 2012; 338: 124–128.
179. Koskela M, Back S, Voikar V, Richie CT, Domanskyi A, Harvey BK et al. Update of neurotrophic factors in neurobiology of addiction and future directions. Neurobiol Dis 2016; 97: 189–200.
180. Wiesel TN. Postnatal development of the visual cortex and the influence of environment. Nature 1982; 299: 583–591.
181. Elbert T, Pantev C, Wienbruch C, Rockstroh B, Taub E. Increased cortical representation of the fingers of the left hand in string players. Science 1995; 270: 305–307.
182. Kuhl PK. Brain mechanisms in early language acquisition. Neuron 2010; 67: 713–727.
183. Leppänen JM, Nelson CA. Tuning the developing brain to social signals of emotions. Nat Rev Neurosci 2009; 10: 37–47.
184. Hensch TK, Fagiolini M, Mataga N, Stryker MP, Baekkeskov S, Kash SF. Local gaba circuit control of experience-dependent plasticity in developing visual cortex. Science 1998; 282: 1504–1508.
185. Huang ZJ, Kirkwood A, Pizzorusso T, Porciatti V, Morales B, Bear MF et al. Bdnf regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. Cell 1999; 98: 739–755.
186. Bavelier D, Levi DM, Li RW, Dan Y, Hensch TK. Removing brakes on adult brain plasticity: from molecular to behavioral interventions. J Neurosci 2010; 30: 14964–14971.
187. Wang D, Fawcett J. The perineuronal net and the control of cns plasticity. Cell Tissue Res 2012; 349: 147–160.
188. Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett JW, Maffei L. Reactivation of ocular dominance plasticity in the adult visual cortex. Science 2002; 298: 1248–1251.
189. Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN et al. Chondroitinase abc promotes functional recovery after spinal cord injury. Nature 2002; 416: 636–640.
190. Gogolla N, Caroni P, Luthi A, Herry C. Perineuronal nets protect fear memories from erasure. Science 2009; 325: 1258–1261.
191. Scali M, Begenisic T, Mainardi M, Milanese M, Bonifacino T, Bonanno G et al. Fluoxetine treatment promotes functional recovery in a rat model of cervical spinal cord injury. Sci Rep 2013; 3: 2217.
192. Morishita H, Miwa JM, Heintz N, Hensch TK. Lynx1, a cholinergic brake, limits plasticity in adult visual cortex. Science 2010; 330: 1238–1240.
193. Maya Vetencourt JF, Tiraboschi E, Spolidoro M, Castrén E, Maffei L. Serotonin triggers a transient epigenetic mechanism that reinstates adult visual cortex plasticity in rats. Eur J Neurosci 2011; 33: 49–57.
194. Putignano E, Lonetti G, Cancedda L, Ratto G, Costa M, Maffei L et al. Developmental downregulation of histone posttranslational modifications regulates visual cortical plasticity. Neuron 2007; 53: 747–759.
195. Silingardi D, Scali M, Belluomini G, Pizzorusso T. Epigenetic treatments of adult rats promote recovery from visual acuity deficits induced by long-term monocular deprivation. Eur J Neurosci 2010; 31: 2185–2192.
196. Yang EJ, Lin EW, Hensch TK. Critical period for acoustic preference in mice. Proc Natl Acad Sci USA 2012; 109: 17213–17220.
197. Gervain J, Vines BW, Chen LM, Seo RJ, Hensch TK, Werker JF et al. Valproate reopens critical-period learning of absolute pitch. Front Syst Neurosci 2013; 7: 102.
198. Maya-Vetencourt JF, Baroncelli L, Viegi A, Tiraboschi E, Castrén E, Cattaneo A et al. Igf-1 restores visual cortex plasticity in adult life by reducing local gaba levels. Neural Plast 2012; 2012: 250421.
199. Sale A, Maya Vetencourt JF, Medini P, Cenni MC, Baroncelli L, De Pasquale R et al. Environmental enrichment in adulthood promotes amblyopia recovery through a reduction of intracortical inhibition. Nat Neurosci 2007; 10: 679–681.
200. Greifzu F, Pielecka-Fortuna J, Kalogeraki E, Krempler K, Favaro PD, Schluter OM et al. Environmental enrichment extends ocular dominance plasticity into adulthood and protects from stroke-induced impairments of plasticity. Proc Natl Acad Sci USA 2014; 111: 1150–1155.
201. Spolidoro M, Baroncelli L, Putignano E, Maya-Vetencourt JF, Viegi A, Maffei L. Food restriction enhances visual cortex plasticity in adulthood. Nat Commun 2011; 2: 320.
202. Mcewen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P et al. The neurobiological properties of tianeptine (stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010; 15: 237–249.
203. Popova D, Ágústsdóttir A, Lindholm J, Mazulis U, Akamine Y, Castrén E et al. Combination of fluoxetine and extinction treatments forms a unique synaptic protein profile that correlates with long-term fear reduction in adult mice. Eur Neuropsychopharmacol 2014; 24: 1162–1174.
204. Hagihara H, Takao K, Walton NM, Matsumoto M, Miyakawa T. Immature dentate gyrus: an endophenotype of neuropsychiatric disorders. Neural Plast 2013; 2013: 318596.
205. Acler M, Robol E, Fiaschi A, Manganotti P. A double blind placebo rct to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol 2009; 256: 1152–1158.
206. Jorge RE, Acion L, Moser D, Adams HPJ, Robinson RG. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry 2010; 67: 187–196.
207. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C et al. Fluoxetine for motor recovery after acute ischaemic stroke (flame): a randomised placebo-controlled trial. Lancet Neurol 2011; 10: 123–130.
208. Normann C, Schmitz D, Furmaier A, Doing C, Bach M. Long-term plasticity of visually evoked potentials in humans is altered in major depression. Biol Psychiatry 2007; 62: 373–380.
209. Vialou V, Feng J, Robison AJ, Nestler EJ. Epigenetic mechanisms of depression and antidepressant action. Annu Rev Pharmacol Toxicol 2013; 53: 59–87.
210. Karpova NN. Role of bdnf epigenetics in activity-dependent neuronal plasticity. Neuropharmacology 2014; 76(Pt C): 709–718.
211. Bear MF, Singer W. Modulation of visual cortical plasticity by acetylcholine and noradrenaline. Nature 1986; 320: 172–176.
212. Chang WH, Bang OY, Shin YI, Lee A, Pascual-Leone A, Kim YH. Bdnf polymorphism and differential rtms effects on motor recovery of stroke patients. Brain Stimul 2014; 7: 553–558.